Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omadacycline vs Moxifloxacin for Community-Acquired Bacterial Pneumonia
NCT02531438Phase 3Completed
- Sponsor
- Paratek Pharmaceuticals
- Start
- Nov 2015
- Primary completion
- Feb 2017
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of omadacycline in community-acquired bacterial pneumonia (CAP) (2 arms), sponsored by Paratek Pharmaceuticals. Primary endpoint: Early Clinical Response. Started Nov 2015; status: completed.
02
Drugs
omadacycline
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT02531438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531438.